|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Real-world off-label use of SGLT2 inhibitors among patients with type 1 diabetes accounted for a small proportion of overall SGLT2 inhibitor use.
|
31601640 |
2020 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this article we have used consensus expert opinion alongside the available evidence, product indication and most recent clinical guidance to provide support for the diabetes healthcare community regarding the appropriate use of SGLT2 inhibitors, focussing on specific considerations for appropriate prescribing of dapagliflozin within the T1DM management pathway.
|
31813092 |
2020 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Efficacy and Safety of SGLT2 Inhibitors in Type 1 Diabetes After the Introduction of an Off-Label Use Protocol for Clinical Practice.
|
31644310 |
2020 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of medications that lower glucose in type 2 diabetes patients independent of insulin action, and have been studied for use in the type 1 diabetes population.
|
31807264 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Given the cardiorenal protective effects of SGLT2 inhibition (SGLT2i), our aim was to examine: 1) the relationship between serum copeptin, metabolic, renal and systemic hemodynamic parameters in adults with T1D; and 2) serum copeptin after SGLT2i with empagliflozin.
|
31816431 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
These trials studied SGLT2 inhibitors (dapagliflozin and empagliflozin) and a dual SGLT1 and SGLT2 inhibitor (sotagliflozin), and demonstrated that these oral non-insulin antihyperglycaemic medications are able not only to improve glycaemic control, but also to reduce body weight and extend time in range without increasing rates of hypoglycaemia in type 1 diabetes.
|
31183975 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Their proposal merits evaluation in a clinical trial involving type 1 diabetes, which should also assess the possible cardiorenal benefits demonstrated with treatment with SGLT2 inhibitors in type 2 diabetes.
|
31334593 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have shown that "euglycemic DKA" in patients with type 1 diabetes receiving a sodium-glucose cotransporter 2-inhibitor (SGLT2i) is due to normal increases in rates of ketogenesis but blunted increases in plasma glucose levels.
|
30688521 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate effects of the dual sodium-glucose cotransporter (SGLT) 1 and SGLT2 inhibitor sotagliflozin in combination with insulin on glucose time in range (TIR) and glucose excursions, postprandial glucose (PPG), and other glycemic metrics in adults with type 1 diabetes using masked continuous glucose monitoring (CGM).
|
30833371 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
SGLT2 inhibitors were proved to be effective in glycemic control and weight loss in T1DM.
|
30565398 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, these results indicate that it is advisable to estimate the renal threshold for glucose reabsorption prior to initiating SGLT2 inhibitor therapy in patients with T1DM.
|
31197753 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
These considerations raise important questions about the risk-to-benefit profile of SGLT2 inhibitors when used as adjunctive therapy in patients with type 1 diabetes.
|
31585721 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Positive data from randomized controlled trials of the SGLT-2 inhibitor dapagliflozin have led to the approval of dapagliflozin as an adjunct to insulin in adults with T1D having body mass index ≥27 kg/m<sup>2</sup> in whom insulin does not provide adequate glycaemic control in Europe and to approval as an adjunct to insulin for adults with T1D in Japan.
|
31081593 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dapagliflozin is the first SGLT2 inhibitor to be approved for use in T1D and, while further clinical experience in T1D is required to more definitively establish its efficacy and safety profile, it provides a promising adjunctive treatment option for adults with T1D and a BMI of ≥ 27 kg/m<sup>2</sup>, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.
|
31664708 |
2019 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus.
|
29663292 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sotagliflozin is the first oral SGLT1 and SGLT2 inhibitor developed for the treatment of adult patients with T1DM, in adjunct with insulin, and has the potential to address unmet needs for patients with T1DM and possibly T2DM, with a favorable benefit/risk profile.
|
29916741 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Non-insulin agents such as SGLT2-inhibitors show beneficial aspects in people with type 1 diabetes.
|
29796246 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Add-on SGLT2 inhibitor therapy might be advantageous for type 1 diabetes, but its use should be considered carefully.
|
29451721 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
To identify and evaluate the recent trials of sodium-glucose cotransporter 1 and 2 (SGLT1 and SGLT2, respectively) inhibitor use in patients with type 1 diabetes (T1D).
|
29794497 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evaluate the efficacy and safety of the dual sodium-glucose cotransporter 1 (SGLT1) and SGLT2 inhibitor sotagliflozin in combination with optimized insulin in type 1 diabetes (T1D).
|
29937430 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, the authors discuss the efficacy and safety of non-insulin therapies, including pramlintide, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 inhibitors (DPP-4), sodium-glucose cotransporter (SGLT1 and SGLT2) inhibitors, metformin, sulfonylureas, and thiazolidinediones as add-on therapies to insulin in T1D.
|
29991320 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
The current study lends supports for the development of SGLT2 inhibitors in combination with insulin as a treatment option for patients with type 1 diabetes.
|
29317332 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis.
|
28276512 |
2017 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
A review of the identified literature indicated that there is a potential role for the combination of SGLT-2 inhibitors with insulin in T1DM for improving glycemic control without increasing the risk of hypoglycemia.
|
28535688 |
2017 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess the effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, on glycemic parameters and measures of glucose variability assessed by a 9-point self-monitoring blood glucose (SMBG) and continuous glucose monitoring (CGM) profiles, and patient-reported outcomes as an add-on to insulin among participants with type 1 diabetes.
|
27899497 |
2017 |